Telix Granted TGA Priority Review for Prostate Cancer Imaging
Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography (PET).
Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.
Activity Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging product.